<?xml version="1.0" encoding="UTF-8"?>
<p id="Par93">The increase in median PFS of 9 months is within the range (7â€“10 months) of improvements observed with maintenance therapy in first-line myeloma treatment [
 <xref ref-type="bibr" rid="CR23">23</xref>, 
 <xref ref-type="bibr" rid="CR24">24</xref>]. In addition, note that the proposed protocol treatment includes both further consolidation and maintenance, and hence the anticipated difference could reasonably be expected to be within this range even in participants with relapsed disease.
</p>
